The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Open accessPublished version of a preprint
Abstract
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of PD-1 with its ligands programmed death-ligand 1 or 2 (PD-L1 or PD-L2) induces tyrosine phosphorylation of the PD-1 cytoplasmic domain by phosphorylating kinase Lck and subsequent recruitment of cytosolic tyrosine phosphatase SHP-2 and PD-1-associated SHP-2 preferentially dephosphorylates CD28 and suppresses CD28 costimulatory signaling leading to restrained effector T cell function (49”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell-surface receptors was shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Hui et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“SHP2 also has effects on parallel pathways (e.g., JAK/STAT signaling) and is implicated as an effector of inhibitory signaling by PD-1 and some other immune checkpoint receptors (Hui et al., 2017; Peled et al., 2018; Yokosuka et al., 2012).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Hui et al., 2017
In the citing paper
“Among these, CD28 has recently been found to be the primary target (45).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [45]
In the citing paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hui et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Flagged first, then by citations
Cited by
Sorted by citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Self-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,248
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 2,054
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 2,054
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,620
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,431
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,351
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,153
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
“, 2017), CD28 co-stimulatory signals (Hui et al., 2017; Kamphorst et al., 2017), patient microbiota (Matson et al.”
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Re, D. P. D., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019) · Physiological Reviews · doi:10.1152/physrev.00022.2018 · Cited by 994
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 909
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Kochin, V., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 823
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Dammeijer, F. F., van Gulijk, M., Mulder, E. E. A. P., Lukkes, M. M., Klaase, L., van den Bosch, T. P. P., van Nimwegen, M., Lau, S. P., Latupeirissa, K., Schetters, S. T. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.001 · Cited by 718
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 670
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 674
Yang, R., Sun, L., Li, C.-F., Wang, Y.-H., Yao, J., Li, H., Yan, M., Chang, W., Hsu, J.-M., Cha, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21099-2 · Cited by 656
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 587
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Qing, T., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 580
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lönberg, N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 572
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 556
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 552
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 494
Role of PD-1 during effector CD8 T cell differentiation
Ahn, E., Araki, K., Hashimoto, M., Li, W., Riley, J. L., Cheung, J., Sharpe, A. H., Freeman, G. J., Irving, B. A., & Ahmed, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718217115 · Cited by 486
Self-citationLXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.026 · Cited by 476
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell surface receptors has been shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients (Hui et al., 2017; Iwai et al., 2005; Leach et al., 1996).”
Precursor exhausted T cells: key to successful immunotherapy?
Kallies, A., Zehn, D., & Utzschneider, D. T. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0223-7 · Cited by 483
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 507
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R. A., Tótpál, K., Chiu, H. H., Wu, Y., Comps‐Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 466
Self-citationPD-1 Controls Follicular T Helper Cell Positioning and Function
Shi, J., Hou, S., Fang, Q., Liu, X., Liu, X., & Qi, H. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.012 · Cited by 453
Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429
Self-citationT‐cell exhaustion in HIV infection
Fenwick, C. W., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., & Pantaleo, G. (2019) · Immunological Reviews · doi:10.1111/imr.12823 · Cited by 429
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Li, J., Li, S., He, Q., Yang, B., & Cao, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 431
Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383
Self-citationDendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Nowicki, T. S., Hu‐Lieskovan, S., & Ribas, A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000303 · Cited by 408
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Simon, S., & Labarrière, N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1364828 · Cited by 420
Programmed death ligand 1 signals in cancer cells
Kornepati, A. V. R., Vadlamudi, R. K., & Curiel, T. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-021-00431-4 · Cited by 411
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I. S., Cohen, I., Maeda, M., Shindo, M., Şenbabaoğlu, Y., Watson, M. J., Leftin, A., Maniyar, R. R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 401
Xia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 397
Ross-Adams, H., Ball, S., Lawrenson, K., Halim, S., Russell, R., Wells, C. A., Strand, S., Orntoft, T., Larson, M., Armasu, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget · Cited by 392
Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
Zhao, Y., Shao, Q., & Peng, G. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0344-8 · Cited by 382
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821218116 · Cited by 359
Banta, K. L., Xu, X., Chitre, A. S., Au‐Yeung, A., Takahashi, C., O’Gorman, W. E., Wu, T. D., Mittman, S., Cubas, R. A., Comps‐Agrar, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.005 · Cited by 384
Self-citationImproving radiotherapy in cancer treatment: Promises and challenges
Chen, H. H. W., & Kuo, M. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18409 · Cited by 398
An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
Klement, J. D., Paschall, A. V., Redd, P. S., Ibrahim, M. L., Lu, C., Yang, D., Celis, E., Abrams, S. I., Ozato, K., & Liu, K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123360 · Cited by 372
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Qin, W., Hu, L.-P., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02298 · Cited by 388
Who's In and Who's Out—Compositional Control of Biomolecular Condensates
Ditlev, J. A., Case, L. B., & Rosen, M. K. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.08.003 · Cited by 350
Liu, C., Liu, X., Xiang, X., Pang, X., Chen, S., Zhang, Y., Ren, E., Zhang, L., Liu, X., Lv, P., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01098-0 · Cited by 364
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0272 · Cited by 349
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 344
An update on lipid oxidation and inflammation in cardiovascular diseases
Zhong, S., Li, L., Shen, X., Li, Q., Xu, W., Wang, X., Tao, Y., & Yin, H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.036 · Cited by 342
Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy
Xie, F., Zhou, X., Fang, M., Li, H., Su, P., Tu, Y., Zhang, L., & Zhou, F. (2019) · Advanced Science · doi:10.1002/advs.201901779 · Cited by 330
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., Guillebon, É. D., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S. M., & Tartour, É. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 330
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 329
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318
Menk, A. V., Scharping, N. E., Rivadeneira, D. B., Calderon, M. J., Watson, M. J., Dunstane, D., Watkins, S. C., & Delgoffe, G. M. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171068 · Cited by 322
Metabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 320
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 307
Regulation of Transmembrane Signaling by Phase Separation
Case, L. B., Ditlev, J. A., & Rosen, M. K. (2019) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-052118-115534 · Cited by 304
Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z. G., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 303
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 295
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 297
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martín‐Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Nicolás, M. A.-S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 306
Andrews, L. P., Butler, S. C., Cui, J., Cillo, A. R., Cardello, C., Liu, C., Brunazzi, E. A., Baessler, A., Xie, B., Kunning, S. R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.016 · Cited by 302
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Deak, L. C., Nicolini, V., Hashimoto, M., Karagianni, M., Schwalie, P. C., Lauener, L., Varypataki, E. M., Richard, M., Bommer, E., Sam, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05192-0 · Cited by 286
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Buchan, S. L., Rogel, A., & Al‐Shamkhani, A. (2017) · Blood · doi:10.1182/blood-2017-07-741025 · Cited by 282
PD1 signal transduction pathways in T cells
Arasanz, H., Gato, M., Zuazo, M., Ibáñez-Vea, M., Breckpot, K., Kochan, G. T., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 287
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265
Molecular mechanism of SHP2 activation by PD-1 stimulation
Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H., Kirkpatrick, J., Ríos, P., Schamel, W. W. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 277
Pang, K., Shi, Z., Wei, L., Yang, D. F., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J., Chen, Y.-A., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 268
Wu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez‐Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 273
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J. N., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 269
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 259
Fessas, P., Lee, H., Ikemizu, S., & Janowitz, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.002 · Cited by 266
IFN-γ: A cytokine at the right time, is in the right place
Burke, J. D., & Young, H. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.002 · Cited by 272
Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment
Borst, L., van der Burg, S. H., & van Hall, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2095 · Cited by 248
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180870 · Cited by 248
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Kowanetz, M., Zou, W., Gettinger, S. N., Koeppen, H., Kockx, M. M., Schmid, P., Kadel, E. E., Wistuba, I. I., Chaft, J. E., Rizvi, N. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802166115 · Cited by 239
Self-citationPhase separation in immune signalling
Xiao, Q., McAtee, C. K., & Su, X. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00572-5 · Cited by 232
Self-citationIdentification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231
Targeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 232
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Yuan, X., Bu, H., Zhou, J., Yang, C., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 221
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
Jung, I.-Y., Kim, Y.-Y., Yu, H.-S., Lee, M., Kim, S., & Lee, J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0030 · Cited by 226
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0342-x · Cited by 219
The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01663-0 · Cited by 240
Zhu, X., Li, K., Liu, G., Wu, R., Zhang, Y., Wang, S., Xu, M., Lu, L., & Li, P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2249143 · Cited by 220
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Chu, X., Tian, W., Wang, Z., Zhang, J., & Zhou, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01800-3 · Cited by 232
Metadata
- Authors
- Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., & Vale, R. D.
- Affiliations
- Howard Hughes Medical Institute (US)
- Genentech (US)
- University of Chicago (US)
- Corresponding author
- Mellman, Ira
- Vale, Ronald D.
- ORCID
- Venue
- Science
- Published
- 2017-03-31
- Volume
- 355
- Issue
- 6332
- Pages
- 1428-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286077
- OpenAlex
- W2592133876
- Cited by
- 1,689
- References
- 68
- Citations by year
- 2026: 121 · 2025: 158 · 2024: 201 · 2023: 203 · 2022: 193 · 2021: 218 · 2020: 224 · 2019: 159 · 2018: 143 · 2017: 63
- FWCI
- 70.99
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Chicago Biomedical Consortium
- NIH (R21AI120010, R00AI106941)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, CD28, PD-L1, T cell costimulation, T cell receptor signaling, SHP2, receptor dephosphorylation, T cell activation, anti-PD-1 therapy, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Phosphorylation, T-Lymphocytes, CD28 Antigens, Jurkat Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
